Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

78%

7 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

7(87.5%)

N/A

1(12.5%)

8Total

Phase 4(7)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04389476Unknown

The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes

Role: lead

NCT04426565Not ApplicableUnknown

The Follow-up Study for the Patients of Illicit Substance Use Disorder

Role: lead

NCT04181567Phase 4Completed

Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients

Role: lead

NCT04093960Phase 4Terminated

Escitalopram Plus PS128 vs. Escitalopram

Role: lead

NCT02704962Phase 4Completed

Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine

Role: lead

NCT01615185Phase 4Terminated

A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia

Role: lead

NCT02032576Phase 4Completed

Predictors of the Response and Relapse/Recurrence After ECT for Depressed Patients

Role: lead

NCT01075529Phase 4Completed

Early Prediction of Fluoxetine Response

Role: lead

NCT00998608Phase 4Terminated

Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia

Role: lead

All 9 trials loaded